Lytix Biopharma AS (OSL:LYTIX) Institutional Ownership: 3.58% (As of Aug. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:LYTIX Lytix Biopharma AS OSL:LYTIX
21 GF Score
Price kr7.50
GF Value kr0.17
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS Institutional Ownership?

Lytix Biopharma AS OSL:LYTIX 21 Institutional Ownership is 3.58% as of Aug. 23, 2026. GuruFocus rates OSL:LYTIX with a GF Score™ of 21/100 and a GF Value™ of kr0.17 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lytix Biopharma AS's institutional ownership is 3.58%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lytix Biopharma AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lytix Biopharma AS's Float Percentage Of Total Shares Outstanding is 0.00%.

Lytix Biopharma AS Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Lytix Biopharma AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS Institutional Ownership Chart

Lytix Biopharma AS Historical Data

The historical data trend for Lytix Biopharma AS can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 3.69 3.65 3.65 3.66 3.58 3.58 3.58 3.58 3.58 3.58
OSL:LYTIX
21GF Score
Lytix Biopharma AS OSL:LYTIX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lytix Biopharma AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.58% mean?
Lytix Biopharma AS (OSL:LYTIX) has a Institutional Ownership of 3.58% as of Aug. 23, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Lytix Biopharma AS and its competitors.
Is Lytix Biopharma AS's Institutional Ownership too high?
Lytix Biopharma AS's current Institutional Ownership is 3.58%. Overall, Lytix Biopharma AS has a GF Score™ of 21/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's Institutional Ownership compare to VRTX and REGN?
Lytix Biopharma AS's Institutional Ownership of 3.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current Institutional Ownership is 3.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Based on GuruFocus' analysis, Lytix Biopharma AS (OSL:LYTIX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.17, compared to a current price of kr7.50 — trading 4311.8% above its estimated fair value. The current Institutional Ownership is 3.58%. Lytix Biopharma AS's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Lytix Biopharma AS (OSL:LYTIX), the current Institutional Ownership is 3.58% as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lytix Biopharma AS (OSL:LYTIX) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of kr7.50 is trading 4311.8% above its estimated GF Value™ of kr0.17. GuruFocus considers Lytix Biopharma AS to be Significantly Overvalued.

Key valuation signals for OSL:LYTIX:

  • Institutional Ownership: 3.58%
  • GF Value™: kr0.17 vs. price of kr7.50 (4311.8% above fair value)
  • GF Score™: 21/100 with 2 warning signs

No single metric tells the full story. See the OSL:LYTIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lytix Biopharma AS Business Description

Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
21GF Score

Get the complete analysis for OSL:LYTIX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr7.50
Price
kr0.17
GF Value